2023
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficients
2022
P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer
Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.Peer-Reviewed Original ResearchStrong CYP3A inducersBreakthrough ovulationCYP3A inducersE2 concentrationsP4 concentrationsMedian ageOvulation suppressionImplant usersPg/Baseline serum concentrationsContraceptive implant usersEtonogestrel implant usersSerum E2 concentrationsParticipants' median ageSerum P4 concentrationsENG implant usersDrug-drug interactionsRifampin exposureMedian durationENG implantMedian BMIEndogenous estradiolSerum concentrationsSurrogate biomarkerWeeks of exposure
2013
ISPMD consensus on the management of premenstrual disorders
Nevatte T, O’Brien P, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundström-Poromaa I, Yonkers K, Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Archives Of Women's Mental Health 2013, 16: 279-291. PMID: 23624686, PMCID: PMC3955202, DOI: 10.1007/s00737-013-0346-y.Peer-Reviewed Original ResearchConceptsPremenstrual disordersGonadotropin-releasing hormone agonistSelective serotonin reuptake inhibitorsRole of oophorectomySecond consensus meetingSerotonin reuptake inhibitorsVitex agnus castusCentral nervous activityCognitive behavioral therapySuppress ovulationOral contraceptivesOvulation suppressionReuptake inhibitorsHormone agonistPsychotropic medicationsCalcium supplementsAlternative therapiesConsensus recommendationsSex steroidsConsensus meetingNervous activityConsensus conferenceCareful diagnosisBehavioral therapyAgnus castus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply